Clinical Trials Logo

Filter by:
NCT ID: NCT05656820 Recruiting - Clinical trials for Bicuspid Aortic Valve Disease

Bicuspid Echocardiac Study Team(BEST)

BEST
Start date: July 1, 2022
Phase:
Study type: Observational

The Chinese Bicuspid Aortic Valve (BAV) Ultrasound imaging cohort study is a Chinese BAV ultrasound imaging cohort study. At present, a retrospective study cohort involving more than 30 hospitals has been established. The prospective multi-center study of BAV is expected to include and follow up 200 outpatients and inpatients with BAV. The clinical, ultrasound imaging and treatment parameters of the patients are collected and the patients are followed up for 2 years. To analyze the prognostic characteristics of BAV patients and establish a Chinese BAV database. The primary endpoint was all-cause death, and the secondary endpoints were heart failure, angina, severe aortic stenosis, severe aortic insufficiency, ascending aortic diameter ≥50mm, and surgery (surgical and interventional). According to the different pathological types of aortic valve in different types of BAV, ultrasound imaging was used to evaluate the different forms of valvular leaflet lesions and prognosis. Finally, it provides a basis for the prognosis, treatment method, treatment timing and treatment plan selection of BAV patients, and lays a foundation for the mechanism study of BAV arterial lesions and the establishment of risk model for the prognosis of BAV patients.

NCT ID: NCT05656599 Enrolling by invitation - Clinical trials for Hematopoietic Stem Cell Transplantation

Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

Start date: January 3, 2023
Phase:
Study type: Observational

Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The course and outcome of CMV infection are different clinically, and the mechanism of CMV infection after transplantation has not been clarified. Reconstitution of cellular immunity after HSCT is a critical determinant of the control of CMV infection. Investigators will dynamically monitor the CMV-specific cellular immune reconstitution after HSCT,and analyze the clinical factors and therapy strategies affecting recovery of CMV-specific immunity during 1 year after HSCT.

NCT ID: NCT05656573 Recruiting - Prostate Cancer Clinical Trials

CART-PSMA Cells for Advanced Prostate Cancer

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.

NCT ID: NCT05656443 Completed - COVID-19 Pneumonia Clinical Trials

Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19

Start date: December 19, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.

NCT ID: NCT05656274 Recruiting - Healthy Volunteers Clinical Trials

A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects.

Start date: November 29, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety,tolerability,and pharmacokinetics of multiple-accending dose of JS1-1-01。

NCT ID: NCT05656222 Withdrawn - Overall Survival Clinical Trials

Irinotecan and Anlotinib for Epithelioid Sarcoma

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.

NCT ID: NCT05656131 Recruiting - Clinical trials for Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Start date: November 23, 2022
Phase: Phase 2
Study type: Interventional

This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with or without camrelizumab in the treatment of HRD positive HER2-negative advanced breast cancer.

NCT ID: NCT05656079 Recruiting - Breast Cancer Clinical Trials

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

easy laugh
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of pegylated liposomal doxorubicin/cyclophosphamide/trastuzumab/pertuzumab followed by docetaxel/ trastuzumab/pertuzumab compared with epirubicin/cyclophosphamide followed by docetaxel/trastuzumab/pertuzumab in the adjuvant treatment of early breast cancer.

NCT ID: NCT05656053 Active, not recruiting - Glioma, Malignant Clinical Trials

Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging

Start date: November 15, 2021
Phase:
Study type: Observational [Patient Registry]

The aim of this observational study is to enable rapid diagnosis of molecular biomarkers in patients during surgery by medical imaging and artificial intelligence models, to help clinicians with strategies to maximize safe resection of gliomas. The main questions it aims to answer are: 1. To solve the current clinical shortcomings of intraoperative molecular diagnosis, which is time-consuming and complex, and enables rapid and automated molecular diagnosis of glioma, thus providing the possibility of personalized tumor resection plans. 2. To implement a neuro-navigation platform that combines preoperative magnetic resonance images, intraoperative ultrasound signals and intraoperative ultrasound images to address real-time molecular boundary visualisation and molecular diagnosis for glioma, providing an approach to improve glioma treatment. Participants will read an informed consent agreement before surgery and voluntarily decide whether or not to join the experimental group. they will undergo preoperative magnetic resonance imaging, intraoperative ultrasound, and postoperative genotype identification. Their imaging data, genotype data, clinical history data, and pathology data will be used for the experimental study. The data collection process will not interrupt the normal surgical process.

NCT ID: NCT05655897 Recruiting - Clinical trials for Mitral Regurgitation

Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation

Start date: November 24, 2022
Phase: N/A
Study type: Interventional

To observe and evaluate the safety and efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation through a prospective, multicenter clinical trial using objective performance criteria.